Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

THOMAS A ABRAMS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1184693947
CMS profile
1108915
Location
BOSTON, MA

General Payments · PY2018–2024

$179,835.27

  • Reported across 142 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$20,832.65

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $19,769.05 5
Travel and Lodging $752.98 4
Food and Beverage $310.62 4

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $16,648.60 11
EISAI INC. $4,184.05 2

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $65,726.95 55
PY2019 $30,800.33 48
PY2020 $14,102.50 6
PY2021 $33,967.50 9
PY2022 $4,370.00 3
PY2023 $10,035.34 8
PY2024 $20,832.65 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $2,055.00 04/18/2024 Consulting Fee Undisputed 01/23/2026 1104712569 CMS
AstraZeneca Pharmaceuticals LP $120.65 05/20/2024 Food and Beverage Undisputed 01/23/2026 1105485381 CMS
AstraZeneca Pharmaceuticals LP $29.61 07/24/2024 Food and Beverage Undisputed 01/23/2026 1105537371 CMS
AstraZeneca Pharmaceuticals LP $64.58 10/22/2024 Food and Beverage Undisputed 01/23/2026 1104340482 CMS
AstraZeneca Pharmaceuticals LP $56.66 11/12/2024 Travel and Lodging Undisputed 01/23/2026 1104472634 CMS
AstraZeneca Pharmaceuticals LP $170.00 11/12/2024 Travel and Lodging Undisputed 01/23/2026 1105623517 CMS
AstraZeneca Pharmaceuticals LP $409.51 11/12/2024 Travel and Lodging Undisputed 01/23/2026 1105683625 CMS
AstraZeneca Pharmaceuticals LP $116.81 11/13/2024 Travel and Lodging Undisputed 01/23/2026 1104450926 CMS
AstraZeneca Pharmaceuticals LP $95.78 11/13/2024 Food and Beverage Undisputed 01/23/2026 1104472126 CMS
AstraZeneca Pharmaceuticals LP $8,200.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1104648009 CMS
AstraZeneca Pharmaceuticals LP $5,330.00 12/19/2024 Consulting Fee Undisputed 01/23/2026 1105285203 CMS
Eisai Inc. $1,829.05 06/26/2024 Consulting Fee Undisputed 01/23/2026 1110785313 CMS
Eisai Inc. $2,355.00 11/06/2024 Consulting Fee Undisputed 01/23/2026 1110785315 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.